WuXi Diagnostics

About WuXi Diagnostics

WuXi Diagnostics is a diagnostics company that focuses on integrating multi-omics clinical data from various technologies to provide comprehensive diagnostic solutions. Established in 2018 as a joint venture between WuXi AppTec and the Mayo Clinic, the company aims to bridge diagnostic research with clinical practice. The company is led by CEO Jason Liu.

The firm operates an open-access innovation platform that utilizes clinical big data and algorithms to create diagnostic services and products. This model supports healthcare providers with solutions for the entire disease management process, including screening, early diagnosis, risk assessment, precision diagnosis, clinical decision support, and prognosis management. WuXi Diagnostics serves clients such as hospitals, doctors, pharmaceutical companies, and health insurance groups. Its business model is centered on developing and commercializing a pipeline of diagnostic products and services, often through strategic collaborations. A key product is the Enabling Solution Package (ESP), which uses algorithms for early disease diagnosis and management.

Headquartered in Shanghai, China, WuXi Diagnostics also has a CAP-accredited Independent Clinical Laboratory in Shanghai, an ISO13485-certified production facility in Suzhou, and a research and development center in Rochester, Minnesota, at the Mayo Clinic's headquarters. The company has achieved significant milestones, including a $150 million Series B funding round in February 2021, with investors like Thermo Fisher Scientific, Shiyu Capital, and YF Capital. This funding is intended to enhance its R&D pipeline and expand its global market presence. During the COVID-19 pandemic, WuXi Diagnostics collaborated with Thermo Fisher and the Mayo Clinic to develop antibody tests.